PriapismMANAGEMENT

GENITOURINARY AND REPRODUCTIVE PRESENTATIONS · 12 SECTIONS

⚲

261 items

☷ Legend

⚲

Cardiovascular Presentations66▾

Respiratory Presentations47▾

Neurological Presentations77▾

Gastrointestinal Presentations63▾

Genitourinary and Reproductive Presentations44▾

Acute Kidney Injury (ATN)Acute Kidney Injury (Post-renal)Acute Kidney Injury (Pre-renal)Amniotic Fluid Embolism Balanitis Bladder Rupture Breast Abscess Cystitis Ectopic pregnancy Epididymitis Glomerulonephritis Hematuria (gross)Hydrocele Interstitial Cystitis Mastitis Mittelschmerz Nephrolithiasis Nephrotic Syndrome Flare Nutcracker Syndrome Orchitis Ovarian Cyst Rupture Ovarian torsion Paraphimosis Pelvic Congestion Syndrome Pelvic Inflammatory Disease (PID)Phimosis Priapism Prostatitis Pyelonephritis Renal laceration Ruptured ovarian cyst Testicular torsion Torsion of Appendix Testis Tubo-ovarian abscess Ureteral Rupture Urethritis Urinary Retention Urinary tract infection (uncomplicated)Urolithiasis (renal colic)Vaginal bleeding (non-pregnant)Vaginitis (Bacterial)Vaginitis (Candidal)Varicocele Vulvovaginal Hematoma

Infectious Disease Presentations146▾

Trauma Presentations88▾

Toxicologic Presentations67▾

Psychiatric Presentations25▾

Musculoskeletal and Rheumatologic Presentations89▾

Dermatology Presentations21▾

Environmental and Exposure Presentations26▾

Hematologic and Oncologic Presentations30▾

Pediatric-Specific Presentations13▾

Endocrine and Metabolic Presentations42▾

ENT and Maxillofacial Presentations21▾

Ophthalmologic Presentations15▾

Obstetric Presentations17▾

Systemic and Miscellaneous Presentations15▾

01Approach to the Critical Patient/attcp28

Time critical priorities

›Priapism stabilization

›Duration 4 hours or more as ischemic until proven otherwise

›Urology notification for suspected ischemic priapism

›IV access

›Cardiac monitor for sympathomimetic therapy

›Analgesia plan before corporal procedures

›Penile nerve block option for aspiration and injection

Phenotype recognition

›Priapism type sorting

›Ischemic low flow

›Rigid corpora

›Significant pain common

›Glans often soft

›Non ischemic high flow

›Partial rigidity

›Minimal pain

›Trauma history possible

›Recurrent stuttering

›Repeated self limited episodes

›Sickle cell disease association

Immediate complications and escalation

›Threats and triggers

›Time dependent cavernosal smooth muscle ischemia risk

›Hypotension or arrhythmia during phenylephrine

›Anticoagulation related bleeding during aspiration

›If priapism duration 24 hours or more, early shunt discussion

Hemodynamic and monitoring targets

›Monitoring and safety

›Continuous ECG during intracavernosal phenylephrine

›Blood pressure cycling during injections

›Avoid excessive total phenylephrine dosing in cardiovascular disease

02History/hx33

Core history

›Priapism history elements

›Time of onset

›Pain severity

›Full rigidity versus partial rigidity

›Prior priapism episodes

›Detumescence attempts

›Recent trauma to perineum penis pelvis

›Recent intracavernosal injection therapy for erectile dysfunction

›Phosphodiesterase type 5 inhibitor exposure

›Recreational drug exposure

›Antipsychotic exposure

›Anticoagulant exposure

›Hematologic disease history

Risk factors and comorbidities

›High risk contexts

›Sickle cell disease

›Recent vaso occlusive pain crisis

›Dehydration triggers

›Fever or infection triggers

›Hematologic malignancy

›Leukemia

›Myeloproliferative disorders

›Pelvic malignancy or metastasis

›Neurologic injury or spinal cord pathology

Medication and toxin review

›Drug associated priapism list

›Trazodone exposure

›Atypical antipsychotic exposure

›Cocaine exposure

›Alpha adrenergic blocker exposure

›Testosterone or anabolic steroid exposure

Time dependent counseling

›Duration implications

›4 to 6 hours association with rising ischemic injury risk

›24 hours association with high erectile dysfunction risk

›36 hours association with severe cavernosal necrosis risk

03Physical Exam/exam22

Focused genital exam

›Penile exam domains

›Corpora rigidity

›Fully rigid corpora pattern

›Partially rigid corpora pattern

›Glans and corpus spongiosum softness

›Penile skin integrity

›Puncture marks suggesting prior injection

›Perineal ecchymosis or hematoma

Vascular and systemic exam

›Systemic assessment

›Vital signs

›Volume status clues

›Cardiovascular exam for phenylephrine risk

›Abdominal or pelvic tenderness for trauma

Hematologic and neurologic clues

›Associated findings

›Splenomegaly

›Lymphadenopathy

›Pallor or jaundice

›Focal neurologic deficits

PITFALLS

›Common misses

›Assuming painless priapism is always benign

›Delay in aspiration and phenylephrine for prolonged ischemic priapism

›Missing perineal trauma with non ischemic priapism

04Differential Diagnosis/ddx15

Life threats and must not miss

›High acuity differentials

›Ischemic priapism ICD 10 N48.30

›Sickle cell related priapism ICD 10 D57.0 series

›Leukemia related priapism ICD 10 C95.9

›Penile compartment syndrome concept

Mimics and related entities

›Mimics

›Penile hematoma

›Penile fracture with swelling

›Paraphimosis causing edema

Etiologic buckets

›Etiology categories

›Drug induced priapism

›Hematologic hyperviscosity

›Neurogenic priapism

›Traumatic arteriocavernosal fistula

›Malignancy infiltration

05Laboratory Tests/lt25

Core labs for ischemic suspicion

›Baseline labs

›Complete blood count for anemia leukocytosis thrombocytopenia

›Marked leukocytosis suggesting leukemia

›Thrombocytosis suggesting myeloproliferative disorder

›Basic metabolic panel for renal function before contrast imaging

›Potassium abnormality relevant to transfusion planning

›Coagulation studies for bleeding risk with aspiration

›Elevated INR related to anticoagulant therapy

Hematology directed testing

›Hematologic evaluation

›Reticulocyte count for sickle cell disease hemolysis context

›Acute anemia relative to baseline suggesting severe hemolysis

›Type and screen for anticipated transfusion

›Crossmatch preparation for exchange transfusion scenarios

Cavernosal blood analysis

›Cavernosal blood gas

›Ischemic pattern

›pH less than 7.25

›pO2 less than 30 mmHg

›pCO2 greater than 60 mmHg

›Non ischemic pattern

›pH near normal

›pO2 near arterial

›pCO2 near arterial

PITFALLS

›Lab limitations

›Normal peripheral oxygenation does not exclude ischemic priapism

›Peripheral venous blood gas not a substitute for cavernosal sample

06Diagnostic Tests/dt24

Scoring Systems

›Duration based risk framing

›Time thresholds

›4 hours threshold for urgent ischemic pathway

›24 hours threshold for low success of aspiration and injection

›Erectile hardness scale adjunct

›Fully rigid erection consistent with ischemic priapism phenotype

›Partially rigid erection consistent with non ischemic phenotype

MRI

›MRI roles

›Limited acute emergency role

›Cavernosal smooth muscle viability assessment in prolonged cases

›Pelvic malignancy evaluation when infiltrative cause suspected

›CT roles

›Pelvic trauma evaluation for suspected vascular injury

›Malignancy staging when suggested by history exam labs

›Contrast considerations

›Renal function review

›Allergy history

Ultrasound

›Penile duplex ultrasound

›High flow pattern

›Increased cavernosal arterial inflow

›Possible arteriocavernosal fistula

›Low flow pattern

›Minimal or absent cavernosal arterial inflow

›EAU guideline support for duplex to distinguish types when uncertain

07Disposition/dispo19

Level of care decisions

›Disposition planning

›Ischemic priapism duration 4 hours or more

›ED based definitive therapy attempt

›Urology involvement before discharge

›Non ischemic priapism

›Outpatient urology follow up acceptable if stable

›Return precautions for increasing pain or rigidity

Admission and transfer criteria

›Indications for admission

›Refractory ischemic priapism after aspiration and phenylephrine

›Need for operative shunt

›Sickle cell disease with systemic complications

›Indications for transfer

›No urology capability for shunt or corporal decompression

›Prolonged ischemic priapism with need for advanced intervention

Discharge criteria

›Safe discharge elements

›Full detumescence sustained

›Pain controlled with oral regimen

›Able to void

›Clear recurrence plan and follow up arranged

08Treatment/t46

Ischemic priapism algorithm

›Ischemic pathway

›Analgesia and anesthesia

›Opioid analgesia as needed

›Dorsal penile nerve block option

›Aspiration and irrigation

›Large bore needle 16 to 18 gauge into corpora

›Aspiration of dark blood until bright red return

›Normal saline irrigation to clear clots

›Intracavernosal sympathomimetic

›Phenylephrine preferred agent per AUA and EAU guidance

›Cardiac monitoring during administration

Phenylephrine protocol

›Phenylephrine intracavernosal dosing

›Concentration 100 to 500 microg per mL per AUA guidance

›Typical preparation example 200 microg per mL in normal saline

›Dose 0.5 to 1 mL per injection

›Repeat every 3 to 5 minutes

›Maximum cumulative dose within 1 hour

›EAU pocket guidance maximum 1 mg within 1 hour

›If significant hypertension chest pain or arrhythmia, stop injections

Escalation to surgery

›Refractory ischemic priapism

›If failure after aspiration and phenylephrine, urology for shunt

›Distal corporoglanular shunt options

›Tunneling techniques for refractory cases per EAU discussion

›If priapism duration prolonged with high necrosis risk, early penile prosthesis discussion in specialist pathway

Adjuncts and special etiologies

›Sickle cell disease associated priapism

›Hydration and oxygenation

›IV isotonic fluids

›Supplemental oxygen if hypoxemic

›Analgesia for vaso occlusive pain

›Opioid based regimen as needed

›Hematology involvement

›Exchange transfusion consideration if refractory after urologic measures per hematology literature

›Avoid transfusing to hemoglobin above 100 g/L as general sickle transfusion principle

›Hyperleukocytosis suspected

›Hematology urgent consult

›Leukapheresis consideration in leukemia associated priapism per specialist guidance

Non ischemic priapism management

›High flow pathway

›Observation and analgesia

›Ice packs and perineal compression trials

›Penile duplex ultrasound referral

›Selective arterial embolization for persistent symptomatic cases

Recurrent stuttering priapism prevention

›Recurrence prevention

›Urology follow up for preventive regimen selection

›Alpha adrenergic agonist oral options in selected patients

›PDE5 inhibitor low dose preventive strategy in selected patients per specialist practice

›Hormonal modulation options in selected patients under specialist care

09Special Populations/sp17

Pregnancy

›Pregnancy considerations

›Rare presentation

›Medication exposure review with obstetrics input

›Phenylephrine systemic effects monitoring

Geriatric

›Older adult considerations

›Higher cardiovascular risk with phenylephrine

›Lower dosing strategy consideration

›Strict monitoring for hypertension and arrhythmia

›Higher anticoagulant use prevalence

›Bleeding risk planning for aspiration

Pediatrics

›Pediatric considerations

›Sickle cell disease common etiology

›Early hematology involvement

›Hydration and analgesia support

›Phenylephrine dose reduction

›Lower concentration selection per EAU pocket guidance

›Child safeguarding and trauma evaluation as appropriate

10Background/b17

Epidemiology

›Epidemiology facts

›Priapism definition erection lasting longer than 4 hours unrelated to sexual stimulation

›Ischemic priapism most common subtype

›Sickle cell disease major risk group for recurrent episodes

Pathophysiology

›Mechanisms

›Ischemic priapism

›Veno occlusion with stagnant deoxygenated blood

›Rising acidosis and hypercapnia in corpora

›Time dependent smooth muscle necrosis

›Non ischemic priapism

›Unregulated arterial inflow

›Cavernosal oxygenation preserved

Therapeutic Considerations

›Treatment rationale

›Aspiration reduces compartment pressure and removes acidotic blood

›Phenylephrine causes alpha 1 mediated cavernosal smooth muscle contraction reducing inflow and promoting venous outflow

›Early intervention improves detumescence rates and erectile function preservation

›AUA and EAU guidelines support aspiration plus intracavernosal phenylephrine as first line for acute ischemic priapism

11Patient Discharge Instructions/pdi8

copy discharge instructions

›Discharge instructions

›No sexual activity until pain resolves and urology cleared

›Avoid alcohol and recreational drugs that can trigger recurrence

›Return to ED immediately for erection 4 hours or more

›Return to ED immediately for increasing penile pain or rigidity

›Return to ED immediately for fever or systemic illness symptoms in sickle cell disease

›Follow up with urology within recommended timeframe

›If sickle cell disease, follow up with hematology for recurrence prevention plan

12References/r7

Clinical guidelines and evidence sources

›Guideline sources

›AUA SMSNA Acute Ischemic Priapism Guideline 2021

›AUA SMSNA Diagnosis and Management of Priapism Guideline 2022

›EAU Sexual and Reproductive Health Guidelines priapism chapter

›BAUS priapism patient and professional guidance documents

›Evidence summary on phenylephrine dosing consistent with AUA and EAU ranges

›Source instructions file

Learn More: Priapism→

Comprehensive Clinical Review

Structured, evidence-informed, long-form analysis for deeper understanding.

Evidence & Review

Reviewed by SymptomDx Medical Team · Last reviewed June 16, 2026

SymptomDx is an educational tool for medical professionals. It does not replace clinical judgment. Verify all clinical data and drug dosages with authoritative sources.